Client News

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Congress 2025

Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron

Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting

PL BioScience Announces Conferences Attendance

ReproNovo Announces Clinical Trial Approval Notice for RPN-001 in China

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma

AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer

Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment